Table 1 Patient demographics and baseline characteristics
Parameter | Overall | 25 mg | 50 mg | 100 mg | 150 mg |
|---|---|---|---|---|---|
N = 23 | N = 3 | N = 5 | N = 6 | N = 9 | |
Median age, years (range) | 62.0 (28, 76) | 71.0 (38, 72) | 68.0 (55, 76) | 60.5 (28, 76) | 60.0 (45, 75) |
Male, % | 61 | 33 | 40 | 67 | 78 |
Race, n (%) | |||||
Caucasian | 19 (83) | 2 (67) | 5 (100) | 5 (83) | 7 (78) |
Asian | 2 (9) | 0 | 0 | 1 (17) | 1 (11) |
Other | 2 (9) | 1 (33) | 0 | 0 | 1 (11) |
ECOG, n (%) | |||||
0 | 13 (57) | 3 (100) | 4 (80) | 2 (33) | 4 (44) |
1 | 10 (43) | 0 | 1 (20) | 4 (67) | 5 (56) |
Stage of disease, n (%) | |||||
IIIC | 1 (4) | 0 | 1 (20) | 0 | 0 |
IV | 19 (83) | 2 (67) | 4 (80) | 5 (83) | 8 (89) |
Unknown | 2 (9) | 1 (33) | 0 | 1 (17) | 0 |
N/A | 1 (4) | 0 | 0 | 0 | 1 (11) |
Prior therapy, n (%) | |||||
Chemotherapy | 18 (78) | 0 | 4 (80) | 6 (100) | 8 (89) |
Surgery | 17 (74) | 3 (100) | 4 (80) | 4 (67) | 6 (67) |
Radiotherapy | 11 (48) | 2 (67) | 2 (40) | 3 (50) | 4 (44) |
Other | 13 (57) | 2 (67) | 2 (40) | 5 (83) | 4 (44) |
